Search Results
Sep 02, 2026, 08:30 ET Bypassing the Bottlenecks: Multi-Modality Considerations for Next-Gen Cell and Gene Therapy, Upcoming Webinar Hosted by Xtalks
Register for this webinar to discover how an integrated, multi-omic approach can bridge the gap between molecular design and cellular function, enabling more informed decision-making, reducing development risk and supporting
More news about: Xtalks
Aug 31, 2026, 12:03 ET Probably Genetic Awarded Up to $10M ARPA-H Contract to End the Rare Disease Diagnostic Odyssey with AI
patterns that will dramatically reduce the diagnostic odyssey faced by rare disease patients. Beyond diagnosis, this data will form the backbone of multi-omic phenotype models that link real-world evidence to disease biology and give drug developers insights needed to identify targets, stratify patients, and
More news about: Probably Genetic
Aug 13, 2026, 08:30 ET Genedata Launches AI Agent That Accelerates Biomarker Discovery, Demonstrated in Alzheimer's Disease Research
integrating complex, multi‑modal data at scale can transform biomarker discovery and validation. These new tools are a game changer in the way human multi-omic data are analyzed and biomarkers are discovered," said Carlos Cruchaga, PhD, Professor of Neurology and Genetics at Washington University School of
More news about: Genedata
Aug 11, 2026, 11:40 ET Unlocking High-Quality NGS Data from Challenging Clinical Samples, Upcoming Webinar Hosted by Xtalks
programs.TORONTO, Aug. 11, 2026 /PRNewswire/ -- Extracting meaningful multi-omic insights from DNA and RNA sequencing data generated from challenging clinical specimens remains a common obstacle in biomarker-driven research and clinical
More news about: Xtalks
Aug 11, 2026, 06:37 ET n6 expands global distribution footprint, bringing iconPCR™ and AutoNorm to more scientists across Europe, the Middle East, and Africa
research institutions around the world to reduce failure rates, streamline workflows, and improve data quality across metagenomics, oncology, and multi‑omic applications.For more information, or to find an authorized distributor in your region, visit
More news about: n6
Aug 04, 2026, 08:00 ET PyxisLabs Launches Lab Service and Enterprise License Offerings to Democratize Quantitative Biochemical Omics with Coverage, Speed and Cost on Par with Sequencing
established to commercialize scalable biochemical omics and predictive biology. It is powered by Pyxis, the Matterworks co-scientist, for interpreting omic data to explain phenotypes. Organizations can license Pyxis to interpret data generated on their own high-resolution LC-MS instruments or send samples
More news about: Matterworks
Jul 30, 2026, 08:30 ET Accelerating Custom Spatial Proteomic Panel Development for New Biological Insights, Upcoming Webinar Hosted by Xtalks
address emerging research questions. Attendees will also explore how streamlined custom panel workflows can support flexible multiplex assays and multi-omic spatial analyses.TORONTO, July 30, 2026 /PRNewswire/ -- Multiplex spatial
More news about: Xtalks
Jul 29, 2026, 02:29 ET Photocure ASA: Results for the second quarter of 2026
acquisition of Vesica Health, following our initial minority investment announced earlier this year. Vesica has developed AssureMDx, a commercial-ready multi-omic urine-based biomarker test for the early detection of bladder cancer with performance characteristics that position it among the leading emerging technologies
More news about: Photocure
Jul 29, 2026, 02:25 ET Photocure ASA: Results for the second quarter of 2026
acquisition of Vesica Health, following our initial minority investment announced earlier this year. Vesica has developed AssureMDx, a commercial-ready multi-omic urine-based biomarker test for the early detection of bladder cancer with performance characteristics that position it among the leading emerging technologies
More news about: Photocure
Jul 28, 2026, 08:00 ET Matterworks Launches PyxisLabs to Scale Biochemical Omics and Predictive Biology
established to commercialize scalable biochemical omics and predictive biology. It is powered by Pyxis, the Matterworks co-scientist for interpreting omic data to explain phenotype. Organizations can license Pyxis to interpret data generated on their own high-resolution LC-MS instruments or send samples
More news about: Matterworks
Jul 17, 2026, 10:15 ET Bioinformatics Market worth $34.41 billion by 2031 - Exclusive Report by MarketsandMarkets™
discovery, clinical genomics, and multi-omics studies is fueling the market by enhancing research efficiency and clinical decision-making.Multi-omic integration segment to register fastest growth in bioinformatics market By function, multi-omics integration is expected to register the
More news about: MarketsandMarkets
Jul 15, 2026, 08:45 ET CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development
Medical Officer and Head of Companion Diagnostics at CellCarta. "The opportunity is not to replace pathology. It is to make tissue, images and multi-omic data more quantitative, reproducible and actionable. By combining CellCarta's global laboratory infrastructure, pathologist oversight and regulatory
More news about: CellCarta
Jul 03, 2026, 10:30 ET Biomarkers Market worth $112.10 billion by 2031 | MarketsandMarkets™
discovery and clinical trial design, as well as the expansion of liquid biopsy and minimally invasive biomarker testing.Advancements such as multi-omic panels, AI-enabled analysis, and high-throughput automation empower researchers to detect subtle disease signals earlier and with greater confidence.
More news about: MarketsandMarkets
Jun 25, 2026, 02:00 ET Circulate Health announces exclusive partnership with Reborne to bring its advanced therapeutic plasma exchange protocols to UK for first time
longevity in peer-review journals such as Aging Cell and The Clinical Journal of Apheresis. A recent publication reports, using multi-omic and epigenetic analysis, that therapeutic plasma exchange induces a salutary effect on important biomarkers of aging. Other peer-reviewed work explores
More news about: Reborne; Circulate Health
Jun 24, 2026, 09:00 ET Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions
to male-focused studies. Xella solves for this by leveraging proprietary AI that sequences billions of data points across clinical inputs and multi-omic biomarkers to detect over 130+ conditions specific to female biology, including polyendocrine metabolic ovarian syndrome (PMOS, formerly known as PCOS),
More news about: Xella Health
Jun 24, 2026, 08:00 ET IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
comprehensive, 'high definition' system.IMU uses a simple blood sample to measure the immune system in unprecedented detail, combining high-fidelity multi-omic analysis with proprietary machine learning analytics. IMU is building the world's largest immune dataset, with unrivalled access to patient samples
More news about: Waters Corporation
Jun 24, 2026, 08:00 ET IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
comprehensive, 'high definition' system.IMU uses a simple blood sample to measure the immune system in unprecedented detail, combining high-fidelity multi-omic analysis with proprietary machine learning analytics. IMU is building the world's largest immune dataset, with unrivalled access to patient samples
More news about: Waters Corporation
Jun 22, 2026, 08:00 ET TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million
engineering, and data-driven technologies, including machine learning and generative AI, to enhance and accelerate drug discovery. By integrating multi-omic biological data with proprietary analytical models, the platform enables identification of novel therapeutic targets and supports rational design of
More news about: TrueLab Biopharmaceutical Co., Ltd.
Jun 22, 2026, 08:00 ET TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million
engineering, and data-driven technologies, including machine learning and generative AI, to enhance and accelerate drug discovery. By integrating multi-omic biological data with proprietary analytical models, the platform enables identification of novel therapeutic targets and supports rational design of
More news about: TrueLab Biopharmaceutical Co., Ltd.
Jun 12, 2026, 03:00 ET Beyond the Double Helix: Phinomics Joins "All Access hosted by Andy Garcia" to Explore Hidden Frontiers in Genetics
allaccessptv.com.About Phinomics: Phinomics is a biotechnology company developing an integrated multi-omic platform to explore complex cellular mechanisms and circular DNA dynamics. By building comprehensive biological datasets from matched tissue samples,
More news about: All Access
Jun 11, 2026, 17:15 ET ChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted Therapeutics
patient stratification. Without it, clinical trials are designed to fail, as responders and non-responders cancel each other out. The company's multi-omic endotype framework addresses this directly, integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics
More news about: ChronicleBio
Jun 04, 2026, 11:49 ET Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
precision diagnostics bladder cancer portfolio, extending further reach upstream in the patient evaluation pathway. Vesica Health offers AssureMDx, a multi-omic urine-based biomarker test designed to support risk stratification and identify hematuria patients at increased risk for bladder cancer to improve early
More news about: Photocure
Jun 04, 2026, 11:46 ET Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
precision diagnostics bladder cancer portfolio, extending further reach upstream in the patient evaluation pathway. Vesica Health offers AssureMDx, a multi-omic urine-based biomarker test designed to support risk stratification and identify hematuria patients at increased risk for bladder cancer to improve early
More news about: Photocure
Jun 02, 2026, 07:00 ET Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
therapy developers: Solid's POLARIS-101™ (formerly known as AAV-SLB101) next-generation capsid technology and NanoMosaic's Tessie™ platform for true multi-omic capsid and transgene analytics.
More news about: NanoMosaic
May 28, 2026, 12:30 ET Following Sanctions-Risk Information from Western Partners, the Ministry of Justice of the Kyrgyz Republic Suspends 50 Legal Entities in First-Ever Use of Interagency Law to Crack Down on Malign Foreign Economic Activity
of-justice-of-the-kyrgyz-republic-suspends-50-legal-entities-in-first-ever-use-of-interagency-law-to-crack-down-on-malign-foreign-economic-activity-302784762.htmlSOURCE The Ministry of Justice of the Kyrgyz Republic
More news about: The Ministry of Justice of the Kyrgyz Republic